Synlogic (Nasdaq: SYBX) to Ring The Nasdaq Stock Market Closing Bell
August 25 2017 - 9:00AM
What: Synlogic (Nasdaq:SYBX), a pioneer in
the development of Synthetic BioticTM medicines, a novel class of
living medicines, will visit the Nasdaq MarketSite in Times
Square.
In honor of the occasion, JC Gutiérrez-Ramos, President
& CEO, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Monday, August 28, 2017 – 3:45 p.m. to
4:00 p.m. ET
Synlogic Contact:Elizabeth Wolffe,
Ph.D.510-710-8767liz@synlogictx.com
Nasdaq MarketSite Media Contact:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Synlogic™ Synlogic™ is pioneering the
development of a novel class of living treatments, Synthetic Biotic
medicines, based on its proprietary drug discovery and development
platform. Synlogic uses the tools and principles of synthetic
biology to genetically reengineer beneficial, probiotic microbes
that are designed to perform critical functions missing or damaged
due to disease. Synlogic’s initial pipeline includes Synthetic
Biotic medicines for the treatment of rare genetic diseases, such
as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In
addition, the company is leveraging the broad potential of its
platform to create Synthetic Biotic medicines for the treatment of
more common diseases, including liver disease, inflammatory and
immune disorders, and cancer. Synlogic is collaborating with AbbVie
to develop Synthetic Biotic-based treatments for inflammatory bowel
disease (IBD). For more information, please visit
www.synlogictx.com.
About Nasdaq:Nasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to approximately 3,900 total listings
with a market value of approximately $12 trillion. To learn more,
visit: http://business.nasdaq.com
-NDAQA-
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Apr 2024 to May 2024
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From May 2023 to May 2024